Novartis Back On Track For Growth In Third Quarter

(MENAFN- Swissinfo) At Swiss pharmaceuticals giant Novartis, the negative impact of generic medicines continued to ease in the third quarter. For the full year, management is revising its previous outlook for core operating profit upwards. Select your language

Generated with artificial intelligence. Listening: Novartis back on track for growth in third quarter This content was published on October 27, 2026 - 08:35 2 minutes Keystone-SDA

Deutsch de Novartis ist im dritten Quartal zurück auf Wachstumskurs Original Read more: Novartis ist im dritten Quartal zurück auf Wachstum

According to a statement released on Tuesday, Novartis generated revenue of $14.5 billion (CHF12 billion) in the third quarter. This is 4% higher than in the same period last year. At constant exchange rates, revenue also rose by 4%.

This means that Novartis's business performance is continuing to gain momentum: after the group had reported a decline in revenue in the first quarter due to the launch of generic versions of key blockbuster drugs, it had already returned to a growth trajectory in the second quarter.

Novartis had recently emphasised on several occasions that the erosion caused by generic medicines was likely to have peaked. Key revenue drivers such as Entresto, Promacta and Tasigna lost their patent protection last year. Group CEO Vas Narasimhan had emphasised that the negative impact is likely to be significantly greater in the first half of 2026 than in the second.

More More Big Pharma steps up race for AI-discovered drugs

This content was published on May 30, 2024 AI is speeding up drug discovery but bringing an AI-discovered drug to market won't happen overnight.

Read more: Big Pharma steps up race for AI-discovered

MENAFN27102026000210011054ID1111874721